Lancet Diabetes & Endocrinology

Article	Citations
Epidemiology and determinants of obesity in China	784
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials	651
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study	400
Consensus on diagnosis and management of Cushing's disease: a guideline update	400
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study	366
Risks and burdens of incident diabetes in long COVID: a cohort study	354
Obesity in children and adolescents: epidemiology, causes, assessment, and management	340
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial	322
Thyroid cancer incidence trends by histology in 25 countries: a population-based study	309
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials	306
A global view of the interplay between non-alcoholic fatty liver disease and diabetes	288
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials	271
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	270
Polycystic ovary syndrome	250
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland	242
Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study	230
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	229
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group	225
Health policy and public health implications of obesity in China	224
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study	214
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial	191
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study	190
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records	189
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study	187
Bone fragility in diabetes: novel concepts and clinical implications	184

COVID-19 and metabolic disease: mechanisms and clinical management	169
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial	166
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study	159
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating	156
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England	147
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes	146
Management of diabetes and hyperglycaemia in the hospital	145
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)	143
RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	143
Diagnosis and treatment of primary aldosteronism	138
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase	131
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial	129
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	128
Clinical management and treatment of obesity in China	127
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	123
Nutritional intake and bone health	118
Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases	117
Diabetes, metabolic disease, and telomere length	114
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multic	110
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care	109
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	107
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	106
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	101
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	100
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality	98
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial	96
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings	96
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study	95
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials	94
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial	94
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction	93
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	92
Menopause: a cardiometabolic transition	87
Osteoporosis in men	85
Sexual dimorphism in COVID-19: potential clinical and public health implications	85
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o	84
Diagnosis of thyroid nodules	82
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial	82
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial	81
Acromegaly: pathogenesis, diagnosis, and management	80
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study	79
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	79
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial	78
Obesity in people living with type 1 diabetes	74
Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria	72
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study	72
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	72
A worldwide journey of thyroid cancer incidence centred on tumour histology	72
Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals	68
Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study	66

Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	66
Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis	65
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	64
Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study	63
Adrenal myelolipomas	63
European Commission classifies obesity as a chronic disease	63
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment	62
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	62
Glycaemic management in diabetes: old and new approaches	60
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	59
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study	58
Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study	54
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	54
Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study	53
Catecholamine physiology and its implications in patients with COVID-19	53
Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study	53
Mapping overdiagnosis of thyroid cancer in China	52
Management of menopause: a view towards prevention	52
Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation	52
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	50
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	48
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	47
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data	47
The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial	46
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study	46
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	46
Insulin's centenary: the birth of an idea	46
The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery	45
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	45
Management of thyroid nodules	44
COVID-19 targets human adrenal glands	44
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial	44
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism	42
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	42
Thyroid cancer in the USA: current trends and outstanding questions	41
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records	41
COVID-19 vaccine prioritisation for type 1 and type 2 diabetes	40
The WHO Global Diabetes Compact: a new initiative to support people living with diabetes	39
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study	39
Vitamin D: 100 years of discoveries, yet controversy continues	38
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis	38
Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study	38
Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature	38
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	36
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial	36
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study	36
Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome: the HUNT study	36
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	35
Current insights and emerging trends in early-onset type 2 diabetes	35
Food security and nutrition in the world	35
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmoniz	35
Subclinical hypothyroidism in older individuals	34
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou	33
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants	32
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the	32
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised,	32
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	32
Vitamin D and COVID-19: why the controversy?	32
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis	32
Childhood obesity: a growing pandemic	32
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study	31
FDA approves teplizumab: a milestone in type 1 diabetes	31
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT	30
Treating chronic diseases without tackling excess adiposity promotes multimorbidity	29
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study	29
Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey	28
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity	27
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using	26
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	26
Menopause transition: a golden age to prevent cardiovascular disease	26
Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications	26
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial	25
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease	25
Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study	24
The relevance of T3 in the management of hypothyroidism	24
Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study	24
Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes?	24
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study	24
Ultra-processed food: a global problem requiring a global solution	23
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis	23

Osteoporosis: overlooked in men for too long	23
Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering	23
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study	23
Obesity in China: time to act	23
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study	23
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)	22
Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward	22
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	22
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	22
Teplizumab approval for type 1 diabetes in the USA	22
Diabetes after SARS-CoV-2 infection	22
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	22
Mendelian randomisation and vitamin D: the importance of model assumptions	22
Challenges in investigating risk factors for thyroid cancer	22
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	22
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins	22
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial	22
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	22
Predicting and preventing heart failure in type 2 diabetes	21
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled	21
Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohor	21
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance	20
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme	20
Glucagon, from past to present: a century of intensive research and controversies	20
Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study	19
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	19
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	19
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	19
The actual burden of obesity—accounting for multimorbidity	19
Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets	19
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	18
Impact of the COVID-19 pandemic on transgender and gender diverse health care	18
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	18
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulat	18
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study	18
Association between fetal abdominal growth trajectories, maternal metabolite signatures early in pregnancy, and childhood growth and adiposity: prospective observational multinational INTERBIO-21st fe	18
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	18
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement	17
Insulin therapy development beyond 100 years	17
Opportunities and challenges in closed-loop systems in type 1 diabetes	17
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial	17
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial	16
Diabetic ketoacidosis risk during the COVID-19 pandemic	16
Diabetes, like COVID-19, is a wicked problem	16
Blood lipids after COVID-19 infection	16
Scientific medical conferences can be easily modified to improve female inclusion: a prospective study	15
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	15
Cancer overtakes vascular disease as leading cause of excess death associated with diabetes	14
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	14
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study	14
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	14
Avoiding a legacy of unequal non-communicable disease burden after the COVID-19 pandemic	14
Defining a cure for type 1 diabetes: a call to action	14
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis	14
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations	14
Current diagnostic criteria identify risk for type 2 diabetes too late	14
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	14
Metabolic health in Brazil: trends and challenges	13
Menopause: a turning point for women's health	13
Cardiovascular disease in type 1 diabetes: a continuing challenge	13
The PEN-Plus Partnership: addressing severe chronic non-communicable diseases among the poorest billion	12
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study	12
The contribution of structural racism to metabolic health disparities in the USA	12
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial	12
The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis	12
Screening type 1 diabetes and celiac disease by law	12
Public health emergency or opportunity to profit? The two faces of the COVID-19 pandemic	12
Tirzepatide: a new low for bodyweight and blood glucose	12
Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study	12
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial	12
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study	11
Type 1 diabetes in Finland: past, present, and future	11
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study	11
Osteoporosis in the USA: prevention and unmet needs	11
Telehealth for people with diabetes: poised for a new approach	11
Growing global burden of type 1 diabetes needs multitiered precision public health interventions	11
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	11
Thyroid cancer incidence in children and adolescents	11
Diabetes in Pakistan: addressing the crisis	10
Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses	10
Challenging diabetes stigma starts and ends with all of us	10
Tirzepatide adds hepatoprotection to its armoury	10
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	10
Metabolic health: a priority for the post-pandemic era	10
Mechanisms of ageing: growth hormone, dietary restriction, and metformin	10
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis	10
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	10
Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia	10
Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study	10
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	10
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action	10
National UK guidelines for the management of paediatric craniopharyngioma	10
Semaglutide for obesity: four STEPs forward, but more to come	9
Singapore's “War on Diabetes”	9
Obesity in the USA: diet and lifestyle key to prevention	9